FDA advisers reject experimental stem cell treatment for ALS

Name: WORLD
Price range: $

The FDA voted against the experimental treatment. Associated Press/Photo by Jacquelyn Martin

FDA advisers reject experimental stem cell treatment for ALS

A panel of outside experts for the Food and Drug Administration on Wednesday voted 17-1 that a treatment for Lou Gehrig’s disease has not been shown to be effective. Drugmaker BrainStorm Cell Therapeutics this month tried to get the treatment, called NurOwn, approved for use in patients with mild to moderate Lou Gehrig’s, also called ALS, or amyotrophic lateral sclerosis. The FDA in 2022 rejected an earlier approval application from BrainStorm. The company’s 200-patient study did not show that the therapy extended life, slowed the disease, or improved patient mobility. The FDA convened Wednesday’s panel after ALS patients and advocates submitted a 30,000-signature petition seeking a public meeting.

What other treatments exist for ALS? The FDA in the last year has approved two new drugs to treat the disease. Advocacy groups have increased lobbying efforts in recent years to push the FDA to approve experimental treatments for terminal illnesses like ALS.

Dig deeper: Read Heather Frank’s report in WORLD Magazine about a new stem cell therapy for Alzheimer's.

Lauren Canterberry

Lauren Canterberry is a reporter for WORLD. She graduated from the World Journalism Institute and the University of Georgia with a degree in journalism, both in 2017. She worked as a local reporter in Texas and now lives in Georgia with her husband.